Key Points
- Nektar Therapeutics insider Jonathan Zalevsky sold 5,538 shares on June 15 at an average price of $60.71, totaling about $336,212. After the sale, he still held 15,437 shares, a 26.4% reduction in his ownership.
- The stock was trading up 1.1% and opened at $60.92, with a 50-day moving average of $73.67 and a 200-day moving average of $62.18. Nektar’s market cap is about $2.06 billion, and the stock has ranged from $8.27 to $109.00 over the past year.
- In its latest quarterly results, Nektar reported a loss of $1.82 per share, wider than analysts expected, though revenue of $10.86 million slightly beat estimates. Despite ongoing losses, Wall Street remains broadly constructive, with nine Buy ratings and a consensus Moderate Buy rating.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 5,538 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $60.71, for a total transaction of $336,211.98. Following the sale, the insider directly owned 15,437 shares of the company's stock, valued at approximately $937,180.27. This represents a 26.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Jonathan Zalevsky also recently made the following trade(s):
- On Tuesday, May 19th, Jonathan Zalevsky sold 199 shares of Nektar Therapeutics stock. The stock was sold at an average price of $65.51, for a total transaction of $13,036.49.
Nektar Therapeutics Trading Up 1.1%
NASDAQ NKTR opened at $60.92 on Thursday. The company has a fifty day simple moving average of $73.67 and a 200 day simple moving average of $62.18. The company has a market cap of $2.06 billion, a P/E ratio of -7.24 and a beta of 1.13. Nektar Therapeutics has a 1 year low of $8.27 and a 1 year high of $109.00.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.58) by ($0.24). The firm had revenue of $10.86 million for the quarter, compared to the consensus estimate of $10.69 million. Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%. Equities research analysts forecast that Nektar Therapeutics will post -9.45 EPS for the current fiscal year.
Hedge Funds Weigh In On Nektar Therapeutics
A number of hedge funds have recently made changes to their positions in NKTR. BNP Paribas Financial Markets raised its stake in shares of Nektar Therapeutics by 93.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 210 shares in the last quarter. KBC Group NV acquired a new position in shares of Nektar Therapeutics in the 1st quarter valued at $52,000. Headlands Technologies LLC acquired a new position in shares of Nektar Therapeutics in the 2nd quarter valued at $65,000. State of Wyoming acquired a new position in shares of Nektar Therapeutics in the 1st quarter valued at $67,000. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of Nektar Therapeutics in the 1st quarter valued at $68,000. Institutional investors and hedge funds own 75.88% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the stock. Piper Sandler upped their target price on shares of Nektar Therapeutics from $105.00 to $192.00 and gave the company an "overweight" rating in a research note on Friday, May 8th. HC Wainwright upped their target price on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the company a "buy" rating in a research note on Monday, April 20th. BTIG Research upped their target price on shares of Nektar Therapeutics from $151.00 to $178.00 and gave the company a "buy" rating in a research note on Monday, April 20th. Jefferies Financial Group reiterated a "buy" rating on shares of Nektar Therapeutics in a research note on Wednesday, April 22nd. Finally, Citigroup upped their target price on shares of Nektar Therapeutics from $123.00 to $151.00 and gave the company a "buy" rating in a research note on Tuesday, April 21st. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Nektar Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $149.63.
Check Out Our Latest Stock Analysis on NKTR
Nektar Therapeutics Company Profile
(
Get Free Report)
Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body's immune system to treat cancer and other serious diseases.
Nektar's product portfolio and pipeline include a range of clinical-stage and partnered programs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
